CellMosaic ADC PerKits®

Download Documents
ADC FLYER
APPLICATION NOTE

CellMosaic's ADC PerKits® are designed to prepare antibody-drug conjugates through surface amines or reduced thiols. Some ADC kits are applicable to general payloads with specific functional groups, while others provide selected, standard linker molecules conjugated to a chosen payload. These come with the appropriate reactive modifications to directly attach the payload and linker to your specific antibody of interest. The kits are complete with all the necessary reagents and procedures for attaching the selected payload to your antibody and purifying the final ADC. All you need to provide is your antibody and standard lab equipment.

A typical CellMosaic personalized ADC kit yield approxismately 2-3 mg of final ADC in buffer, with an average Drug-to-Antibody Ratio (DAR) of 2-4. Purity level are typically >90% with less than 5% of unreacted payload remain. Individual results may vary depending on the specific antibody system you are using and the hydrophobicity of your payload. The kit instructions are comprehensive and easy to follow, and the procedure can typically be completed within 6 hours, requiring less than 1-hour of hands-on time.

Other products on the market for antibody screening may use a general secondary antibody or a general antibody affinity coupling (such as protein-A) to provide indirect conjugation. However, these indirect conjugation approaches can significantly affect the hydrodynamic size and physiological behaviors of ADCs (e.g., altering cleavage and degradation mechanisms). As a result, these products do not provide a fully representative approach for evaluating your novel ADC in screening or proof-of-concept (POC) studies.

Perkit™ ADC Selection Guide

Product#	Protein	Drug	Scale of Reaction (Standard Kit)	Labeling Chemistry	Linkage
CM11429	IgG Ab	No drug (VC-PAB linker only)	1-3 mg	Reduced thiol	Releasable
CM51403	IgG Ab	Acid	1-3 mg	Surface amine	Stable
CM11410 (x1, x3)	IgG Ab	DM1	0.1 mg, 1-3 mg	Surface amine	Stable
CM11406 (x1, x3)	IgG Ab	Doxorubicin	1-3 mg	Surface amine	Stable
CM11407 (x1, x3)	IgG Ab	Methotrexate	1-3 mg	Surface amine	Stable
CM11409 (x1, x3)	IgG Ab	MMAE	0.1 mg, 1-3 mg	Reduced thiol	Releasable
CM11422 (x1, x3)	IgG Ab	MMAF	1-3 mg	Reduced thiol	Stable
CM11425 (x1, x3)	IgG Ab	MMAF	1-3 mg	Reduced thiol	Releasable
CM11408 (x1, x3)	IgG Ab	SN38	1-3 mg	Surface amine	Releasable
CM11431 (x1, x3)	IgG Ab	Deruxtecan	1-3 mg	Reduced thiol	Releasable
CM11416 (x1, x3)	F(ab')2	MMAE	0.73-2.2 mg	Reduced thiol	Releasable
CM11419 (x1, x3)	F(ab')2	DM1	0.73-2.2 mg	Surface amine	Stable

(Note: additional kits configurations can be added depending on the request from customers. Please inquire if you do not see your current configuration of interest listed or request a custom bioconjugation service)

AqT™ ADC Drug Development & Manufacturing

In the event that a drug conjugate cannot be made using classical linkers or the effectiveness of the drug conjugates are compromised by the number of toxins loaded onto the antibody using CellMosaic PerKits™ ADC, CellMosaic has developed super-hydrophilic and water soluble AqT™ linker for this purpose. Click here for more information.

Selected Citations from Customers who Use ADC Prepared from CellMosaic's ADC Kits

1. Lofgren, Kristopher A.; Sreekumar, Sreeja; Jenkins, Charles E., Jr.; Ernzen, Kyle J.; Kenny, Paraic A. "Anti-tumor efficacy of an MMAE-conjugated antibody targeting cell surface TACE/ADAM17-cleaved Amphiregulin in breast cancer." Antibody Therapeutics 2021, 4 (4), 252-261.

2. Neetha Parameswaran, Liping Luo, Lingjun Zhang, Joel Chen, Frank P. DiFilippo, Charlie Androjna, David A. Fox, Sarah L. Ondrejka, Eric D. Hsi, Deepa Jagadeesh, Daniel J. Lindner & Feng Lin. "CD6-targeted antibody-drug conjugate as a new therapeutic agent for T cell lymphoma" Leukemia 2023, 37, 2050-2057.

3. Micalizzi, Douglas S.; Che, Dante: Nicholson, Benjamin T.; Edd, Jon F.; Desai, Niyati; Lang, Evan R.; Toner, Mehmet; Maheswaran, Shyamala; Ting, David T.; Haber, Daniel A. "Targeting breast and pancreatic cancer metastasis using a dual-cadherin antibody." PNAS 2022, 43 (119), e2209563119.